Asia Pacific Drug Delivery System Market to 2027 - Regional Analysis and Forecasts by Route of Administration (Transmucosal, Oral, Injectable, Topical, Implantable, and Ocular); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies); and Application (Home Care Settings, Hospitals & Clinics, and Others) and Country

The Asia Pacific drug delivery systems market is expected to reach US$ 441,337.0 Mn in 2027 from US$ 212,012.7 in 2018. The market is estimated to grow with a CAGR of 8.6% from 2019-2027.

The key factors that are driving the growth of the market are rising incidence of chronic diseases, and growing demand for non-invasive drug delivery devices. However, the factors restraining the market growth are high R&D cost involved in product development. Whereas, high cost for developing drug delivery devices is likely to have a negative impact on the growth of the market in the coming years.

In Asia Pacific, various routes of administration are being studied in order to treat these chronic diseases. According to the estimates by The Asia Pacific Burden of Disease, the death rate of CVD is approximately 272 per 100,000 people in India, which is comparatively higher than the Asia Pacific average (i.e., 235 per 100 000 population). Similar trends for the increased prevalence of diabetes is witnessed among Asian countries such as Australia, China, South Korea, and Australia. For instance, as per IDF Diabetes Atlas published by the International Diabetes Federation in 2017, South-East Asia consists of almost one-fifth (19%) of the Asia Pacific diabetes population. As per the data published by the World Health Organization (WHO), in 2014, around 230 million people in China had CVD. Also, by 2030, the number is predicted to increase by 50% considering the aging Chinese population and growth. Additionally, by 2030, cardiovascular disease will cost $ 1,044 billion to the Chinese government. Rising geriatric population and related chronic diseases are expected to drive the sales of medical devices, hence leading to the growth of the market in the Asia Pacific over the forecast years. The problem of growing prevalence of cancer is increasing in APAC.  The region reports Japan, Taiwan, Singapore, South Korea, Malaysia, Thailand, China, Philippines, Sri Lanka, Vietnam, Indonesia, Mongolia, India, Laos, and Cambodia as the top 15 countries with cancer prevalence. Owing to Increasing Chronic Diseases Cases, the drug delivery systems market is likely to propel the growth in the forecast period.

China is anticipated to lead the adoptions of drug delivery systems across the Asia Pacific region through the forecast period. Growing research activities in drug delivery technology, increasing significant prevalence of disease and rising number of collaborations and partnerships in advance science and innovation. China is also expected to provide lucrative opportunities to local as well as international players to manufacture and market drug delivery devices in the country over the forecast years.

China Drug Delivery Systems Market Revenue and Forecasts to 2027 (US$ Mn)

Asia Pacific Drug Delivery Systems Market Segmentation

By Route of Administration

• Oral
  • Solid Oral Drugs
  • Liquid Oral Drugs
  • Semi-solid Oral Drugs
• Transmucosal
  • Pulmonary Drug Delivery
    • In-metered Dose Inhalers
    • Dry Powder Inhalers
    • Nebulizers
  • Nasal Drug Delivery
    • Nasal Sprays
    • Nasal Drops
    • Nasal Gels
  • Buccal Drug Delivery
  • Sublingual Drug Delivery
  • Rectal Transmucosal Drug delivery
  • Vaginal Transmucosal Drug Delivery
• Injectable
  • Conventional Injection Devices
  • Self-Injection Devices
    • Needle Free Injectors
    • Pen Injectors
    • Wearable Injectors
• Topical
  • Semi-solid Topical Drug Delivery Formulations
  • Liquid Topical Drug Delivery Formulations
  • Solid Topical Drug Delivery Formulations
  • Transdermal Patches
  • Transdermal Gels
  • Others
• Implantable
  • Active Implantable
  • Passive Implantable
• Ocular
  • Eye Drops & Sprays
  • Gels & Ointments
  • Ocular Inserts
  • Drug Coated Contact Lenses

• Hospital & Clinics
• Home Care Settings
• Others

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

• Asia Pacific
  • China
  • Japan
  • India

Companies Mentioned

• 3M
• MYLAN N.V.
• ABBOTT
• F. HOFFMANN-LA ROCHE AG
• JOHNSON & JOHNSON
• NOVARTIS
• ANTARES PHARMA
• BAXTER
• MERCK & CO., INC.
• BECTON, DICKINSON AND COMPANY

The List of Companies

1. 3M
2. Mylan N.V.
3. Abbott
4. F. Hoffmann-La Roche AG
5. Johnson & Johnson
6. Novartis
7. Antares Pharma
8. Baxter
9. Merck & Co., Inc.
10. Becton, Dickinson And Company

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Drug delivery system market.

• Highlights key business priorities in order to assist companies to realign their business strategies.

• The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific Drug delivery system market, thereby allowing players across the value chain to develop effective long-term strategies.

• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

• Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.

• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.